L17E selectively directs its actions towards critical immune cells, thereby mitigating inflammation and impeding the progression of debilitating ailments. Through an array of exceptional preclinical investigations, L17E has exhibited remarkable outcomes and presents an unprecedented mechanism of action, instilling steadfast hope towards a paradigm shift in the realm of autoimmune disease management.
CAT No: GR2206
CAS No:2305578-13-4
Synonyms/Alias:L17E; GLXC-25660; 2305578-13-4; DA-54732; Ile-Trp-Leu-Thr-Ala-Leu-Lys-Phe-Leu-Gly-Lys-His-Ala-Ala-Lys-His-Glu-Ala-Lys-Gln-Gln-Leu-Ser-Lys-Leu-NH2
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.